A Phase 2 Study of HS-20093 in Osteosarcoma and Sarcomas
Recruiting Phase 2 NCT05830123
Study Description
Evaluating the Safety and Effectiveness of an Investigational Drug (HS-20093) in Patients with Relapsed or Refractory Osteosarcoma and Other Sarcomas
Study Details
- Registry ID:
- NCT05830123
- Conditions:
- Osteosarcoma, Sarcoma
- Phase:
- Phase 2
- Target Enrollment:
- 170 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (15 sites)
-
Liaoning Tumor Hospital & Institute
Shengyang, China -
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, China -
Sun Yat-sen University Cancer Center
Guangzhou, China -
Hunan Cancer Hospital
Changsha, China -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China -
Henan Cancer Hospital
Zhengzhou, China -
Chinese PLA General Hospital of Eastern Theater Command
Nanjing, China -
Wei Guo
Beijing, Beijing, China -
Peking University People's Hospital
Beijing, China -
Tianjin Cancer Hospital
Tianjin, China -
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China -
Zhejiang Cancer Hospital
Hangzhou, China -
Ruijin Hospital
Shanghai, China -
Shanghai 6th People's Hospital
Shanghai, China -
Shanghai General Hospital
Shanghai, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.